Research programme: adoptive T-cell therapy - Tactiva Therapeutics

Drug Profile

Research programme: adoptive T-cell therapy - Tactiva Therapeutics

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roswell Park Cancer Institute; Tactiva Therapeutics
  • Developer Tactiva Therapeutics
  • Class Antineoplastics; Cell therapies; Immunotherapies
  • Mechanism of Action Cell replacements; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 20 Sep 2017 Tactiva Therapeutics plans phase I/IIa TACT-001 trial for Solid tumours, including ovarian cancer, prostate cancer, pancreatic cancer, non-small cell lung cancer and malignant melanoma in Q1 2018
  • 09 Aug 2017 Research programme: adoptive T-cell therapy - Tactiva Therapeutics is available for licensing as of 09 Aug 2017.
  • 09 Aug 2017 Tactiva Therapeutics in-licenses DEACT technology from Roswell Park Cancer Institute before August 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top